ClinicalTrials.gg
CompletedNCT06887972Updated Nov 16, 2026Results posted

A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

A Phase 4 interventional study of Suzetrigine in Acute Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Treatment

Updated Nov 16, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing suzetrigine in Acute Pain — 3 open to participants now, 3 under way, none of them phase 3. suzetrigine · Acute Pain.

Enrollment
6th of 10
100 · median 165
Started
2025
with 1 other
Phase 4
5 of 10
3 open now
Registered
5th of 10
by date
Lead sponsor
6 of 10
Vertex Pharmaceuticals Incorporated

Among the 10 studies testing suzetrigine in Acute Pain, this one is the 6th largest by enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 5th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.

Browse Acute Pain studies →

Open to participants now

3 of the 10 studies testing suzetrigine in Acute Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing suzetrigine in Acute Pain, or all of them as a file.
02

Study summary

The study evaluates the effectiveness, safety, and tolerability of SUZ as part of multimodal therapy (MMT) in treating acute postoperative pain.

03

Conditions studied

  • Acute Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of greater than or equal to (≥)18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
  • Participants scheduled to undergo an aesthetic or reconstructive surgical procedure that would typically be treated with opioid therapy for at least 72 hours postoperatively

Key Exclusion Criteria:

  • Participated in a previous study with SUZ or received Journavx

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Suzetrigine (SUZ)

    Participants received SUZ 100 milligram (mg) as the loading dose, followed by SUZ 50 mg every 12 hours (q12h) for 14 days or until pain resolves, whichever occurs first.

    Drug: Suzetrigine

Interventions

  • Tablets for oral administration.

    Also known as: VX-548, SUZ, JOURNAVX

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) for Pain Control at the End of Treatment

    The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as poor, fair, good, very good or excellent. Percentage of participants who reported good, very good or excellent on the PGA scale was reported.

    Time frame: Day 14 or at Pain Resolution, whichever occurs first

07

Results

Posted Nov 16, 2026

Participant flow

Participant flow — Overall Study
MilestoneSuzetrigine (SUZ)
Started100
Mfas99
Safety set99
Completed93
Not completed7
Withdrew: Lost to follow-up4
Withdrew: Withdrawal of consent (not due to ae)1
Withdrew: Other1
Withdrew: Enrolled but not dosed1

Outcome measures

PrimaryPercentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) for Pain Control at the End of Treatment

The PGA is a single-item assessment of patient perceptions of the method of pain control with the study drug and is evaluated on a 5-point Likert scale as poor, fair, good, very good or excellent. Percentage of participants who reported good, very good or excellent on the PGA scale was reported.

Time frame:
Day 14 or at Pain Resolution, whichever occurs first
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) for Pain Control at the End of Treatment
Percentage of ParticipantsSuzetrigine (SUZ)
Percentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global Assessment (PGA) for Pain Control at the End of Treatment90.7 (83.1 to 95.7)

Adverse events

Collected over Day 1 up to Day 30. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Suzetrigine (SUZ)0/99 (0%)3/99 (3%)21/99 (21.2%)
Most frequent serious events
Most frequent serious events
EventSuzetrigine (SUZ)
BradycardiaCardiac disorders1/99
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/99
AngioedemaSkin and subcutaneous tissue disorders1/99
Most frequent other events
Most frequent other events
EventSuzetrigine (SUZ)
NauseaGastrointestinal disorders11/99
Blood creatine phosphokinase increasedInvestigations8/99
Procedural nauseaInjury, poisoning and procedural complications6/99

Baseline characteristics

All participants who have received at least 1 dose of study drug, excluding participants who meet one of the postoperative individual stopping rules before discharge/leaving the medical facility.

Age, Continuous
Age, Continuous(Years)Suzetrigine (SUZ)
Mean41.2 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Suzetrigine (SUZ)
Female91
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Suzetrigine (SUZ)
Hispanic or Latino35
Not Hispanic or Latino63
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Suzetrigine (SUZ)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American34
White63
More than one race2
Unknown or Not Reported0
08

Study locations

5 sites
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Beth Israel Deaconess Medical Center - Surgery
    Boston, Massachusetts 02215, United States
  • HD Research LLC | First Surgical Hospital
    Bellaire, Texas 77401, United States
  • Memorial Hermann Village
    Houston, Texas 77043, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Oct 2025, 7 months.

Results were first posted in Nov 2026, 1 year after primary completion.

Of 84 phase 4 interventional studies under Acute Pain, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 21, 2025
StartActual
Mar 21, 2025
Primary completionActual
Oct 24, 2025
CompletionActual
Nov 7, 2025
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportionPercentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global assessmentAssessment (PGA) for Pain Control at the endEnd of TreatmentTime frame: From Day 3 up to Day 14 → Day 14 or at Pain Resolution, whichever occurs first
Nov 16, 2026
Documents
Show all 1 update
  1. Nov 16, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportionPercentage of Participants Reporting Good, Very Good, or Excellent on a Patient Global assessmentAssessment (PGA) for Pain Control at the endEnd of TreatmentTime frame: From Day 3 up to Day 14 → Day 14 or at Pain Resolution, whichever occurs first
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06887972
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Mar 21, 2025
Primary completion
Oct 24, 2025
Completion
Nov 7, 2025
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion